AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05256667 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RCT-TVWD
Description: Group 2- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by intracanal dressing and temporary restoration for 7 days. After 7 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
Study NCT05256667 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: RCT-TVWOD
Description: Group 3- Endodontic treatment in two visits using chemomechanical preparation and passive ultrasonic irrigation, followed by temporary restoration for 2 days, without intracanal dressing. After 2 days, an identical chemomechanical preparation on visit 2 will be performed, followed by obturation and final restoration.
Study NCT05295576 — intervention group
Intervention type: PROCEDURE
Intervention: non surgical periodontal therapy
Description: Scaling and root planing
Study NCT05944926 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Activity Program (HAP)
Description: HAP, delivered over 6-8 sessions by non-specialist healthcare workers, has behavioural activation as the core psychological strategy along with other strategies such as problem-solving and activation of social networks.
Study NCT05944926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant medication (fluoxetine)
Description: Patients assigned to antidepressant medication will start on fluoxetine 20 mg/day and can be raised to 40 mg/day (the maximum mandated by treatment guidelines for primary care in India) at week 3 or 6 for patients who have yet to remit. Participants who do not tolerate fluoxetine can be switched to escitalopram at week 6 (10mg which can be titrated up to 20 mg).
Study NCT06052280 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise program
Description: After the outpatient intensive physical therapy program (common to both study arms), patients in the TrE group will continue with prescribed self-training at home through telerehabilitation, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The TrE arm will be supported by a telerehabilitation device which will be installed and tested at the patients' home immediately after the outpatient intensive program. The device will track any access and exercise duration, so that the physiotherapists will be able to remotely monitor both the actual duration of each session and their weekly frequency. One session per week will be directly and online supervised by a physiotherapist, while the other two will be recorded only.
Study NCT06052280 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home self-exercise program
Description: After the outpatient intensive physical therapy program (common to both study arms), patients in the HSE group will continue with prescribed self-training at home, at least 3 times a week for 4 weeks. Each physical exercise session will consist of at least 5 minutes of aerobic warming-up, 35 minutes of specific high-intensity exercises for PD, and 5 minutes of aerobic cool-down.~The HSE arm will be given a booklet containing detailed explanations and pictures of the assigned exercises, in order to guide them in the correct execution of the requested movements. Subjects in this group will be asked to fill in a training diary to keep track of the training sessions and their duration. Once a week a physiotherapist will contact patients to discuss possible problems encountered in performing the exercises and to help in solving them.
Study NCT06198335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modified Perichondral Approach Thoracoabdominal Nerve block
Description: M-TAPA block will be performed to Group M-TAPA at the end of the surgery, using US (Vivid Q) while the patient is in the supine position After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. The US probe will be placed in the sagittal plane where the midclavicular line intersects with the costal cartilage corresponding to the costochondral angle. Using the In Plane technique, the probe is gently pushed to visualize the lower part of the costochondral angle at the central level, advancing the block needle in the caudal-cranio direction, 5 ml of saline will be injected into the layer between the transverse abdominal muscle and the lower plane of the costal cartilage, and the block location will be confirmed. After the block location is confirmed, a total of 20 ml + 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
Study NCT06198335 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transversus Abdominal Plane block
Description: TAP block will be performed to Group TAP at the end of the surgery, using US (Vivid Q) while the patient is in the supine position. After providing aseptic conditions, the high frequency linear US probe (11-12 MHz, Vivid Q) will be covered with a sterile sheath, and an 80 mm block needle (Braun 360°) will be used. USG will be placed transversely on the mid-axillary line between the iliac crest and subcostal planes. Using the In Plane technique, the block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline. The block needle will be advanced into the fascial plane between the internal oblique and transversus abdominis muscles and the location will be confirmed by administering 5 ml of saline.and than 20 ml of 0.25% bupivacaine (total 40 ml for both sides) will be injected bilaterally
Study NCT06316752 — intervention group
Intervention type: OTHER
Intervention: Observational study
Description: It is an observational study involving non-invasive routine examinations without treatment, thus posing no additional risk to patients. This project does not involve the use of medications, medical techniques, or the market status of medical equipment.
Study NCT05918679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of speech variability on speech motor learning
Description: This intervention will examine whether reducing normal variability of speech could improve error detection and speech motor learning. We will design training tasks to change subjects' speech variability. We will train subjects to decrease/decrease their speech variability. Upon completing the training tasks, subjects will complete a motor learning task.
Study NCT05918679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of error-detection training on speech motor learning
Description: This intervention will examine whether improving subjects' ability to detect and estimate auditory perturbation could improve speech motor learning. For this purpose, we will design training tasks to change subjects' estimation of the perturbation magnitude. After completing the training tasks, subjects will complete the motor learning task.
Study NCT05918679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contributions of error awareness to speech motor learning
Description: This intervention will examine the contributions of error awareness to speech motor learning. Subjects will produce a target word while receiving perturbed auditory feedback with different magnitudes. Subjects will be trained to indicate the magnitude of the error they perceived with or without visual feedback.
Study NCT05918679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhancing auditory-to-motor mapping with augmented visual feedback
Description: This intervention will determine the contributions of enhanced auditory-to-motor mappings to speech motor learning. We will design training tasks in which we will use visual feedback to provide feedback regarding subjects' accuracy of auditory-to-motor mapping.
Study NCT05918679 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effects of enhanced auditory-motor awareness on speech motor learning
Description: In this intervention, subjects will be trained to control their articulators more accurately and be more aware of their articulators' position and their auditory consequences. After the training tasks, subjects will complete a motor learning task.
Study NCT04581330 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEKA SmartXide C02 laser
Description: One pass with a 1-mm spot density and a 60 micron depth will be performed followed by a 1-mm spot density and a 200 micron depth will be used
Study NCT05990985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone hydrochloride liposome injection
Description: Mitoxantrone hydrochloride liposome injection (18 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Study NCT05990985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RiTUXimab Injection
Description: RiTUXimab Injection (375 mg/m\^2) will be administered by intravenous infusion on day 0 in a 3-week treatment cycle.
Study NCT05990985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamid
Description: Cyclophosphamid (750 mg/m\^2) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Study NCT05990985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (1.4 mg/m\^2，maximum dose 2mg ) will be administered by intravenous infusion on day 1 in a 3-week treatment cycle.
Study NCT05990985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Prednisolone (100mg/d) will be administered by intravenous infusion on day 1-5 in a 3-week treatment cycle.
Study NCT05727098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: injection of Bupivacaine 0.25% in ESPB
Study NCT05727098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride and dexmedetomedine
Description: injection of Bupivacaine 0.25% and dexmedetomedine in ESPB
Study NCT05727098 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride and ketamine
Description: injection of Bupivacaine 0.25% and ketamine in ESPB
Study NCT05919615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: Tranexamic Acid: 100 MG/ML Solution for injection
Study NCT05919615 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% sodium chloride normal saline
Study NCT06465836 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: O, lreay suture
Description: bilateral uterine artery ligations as described by O- lreay technique in addition to standard conservative methods. Briefly two large vicryl stitches were passed using a large sized needle below and lateral to the lower edge of the uterine incision angle in anteroposterior direction and then redirected from back to the front through avascular window in the posterior leaf of the broad ligament just lateral to the uterine border taking care to avoid injury to bowel posteriorly or bladder/ureter anteriorly. The stitches were tied securely anteriorly
Study NCT06465836 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: modified O, lreay suture
Description: 1. Pack Douglas- pouch with a towel.~2. Straight the used vicryl needle mostly no 1.~3. Try to compress and approximate anterior and posterior uterine walls.~4. Start from anterior to posterior 3- 4 cm medial to lateral uterine margin and then pass from posterior to anterior through avascular area in the broad ligament. And we repeat the procedure on the other side. We can repeat this method of uterine ligation at another different plane if needed.
Study NCT04042844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BRTX-100
Description: Hypoxic cultured mesenchymal stem cells (MSCs) from autologous bone marrow with autologous platelet lysate.
Study NCT04042844 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Sodium Chloride (0.9%) intravenous infusion preparation is a sterile and non-pyrogenic solution
Study NCT05507294 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glumetinib
Description: Fasting: Subjects are fasted overnight (at least 10 hours before administration) and receive Glumetinib tablets with 240 mL warm water the next morning.~Fed (high-fat meal/low-fat meal): Following an overnight fast for at least 10 hours, subjects finished a high-fat meal, or a low-fat meal within 30 minutes the next morning (eat up all meals). Glumetinib tablets are orally administered by subjects with 240 mL warm water on 30 minutes after starting the meal. Water is allowed as desired except for 1 hour before and 2 hours after administration (including the meal), and no more than 500 mL of water will be consumed including the water intake during the high-fat meals or low-fat meals, and the water for administration. The subjects will be fasted for at least 4 hours after administration, and then have dinner approximately 9 hours after administration.
Study NCT05481190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Exercise Program
Description: Data collection tools were applied to the tele-exercise group and control group at the beginning of the study. For the tele-exercise group, by the researcher, Exp. A 6-week exercise program was created under the consultancy of a physiotherapist. Children who met the research criteria were asked to do these exercises for 20 minutes, 3 times a week for 6 weeks. The exercises were performed online with the researcher at the scheduled time one day a week, and by the children twice a week. On the days they exercised, diaries consisting of semi-structured questions were sent to the children's addresses by cargo and they were allowed to keep a diary. Phone calls were made once a week to provide motivation and increase compliance with exercise. A smart watch was sent to the children by cargo to increase motivation. The children were asked to fill in the follow-up form, which was sent via weekly google forms.
Study NCT05481190 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just observation
Description: Standard care was given to the children in the control group.
Study NCT05786404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIM-DJ2727 - FROZEN
Description: Patients with active UC will receive induction dose of 100 grams of stool via frozen retention enema, Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-FROZEN administered in clinic. This consists of microbiota suspension from well-screened donors. Twice filtered fecal microbiota product diluted in saline to 500 mL containing 100g of study drug will be administered as frozen enema induction dose
Study NCT05786404 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRIM-DJ2727 - CAPSULES
Description: Patients with active UC will receive induction dose of 100 grams of stool in orally administered enteric-coated capsules Fecal Microbiota Transplantation (FMT) product manufactured as PRIM-DJ2727-CAPSULES.These capsules consists of microbiota from well-screened donors. The induction dose of enteric-coated capsules will be derived from 100 grams stool.
Study NCT03515031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High Flow Nasal Cannula Oxygenation
Description: Delivery of humidified and heated (37ºC) high flow oxygen
Study NCT03515031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi Mask Oxygenation
Description: delivery of high flow oxygen
Study NCT04999527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DISC-0974
Description: DISC-0974 is administered (IV infusion or Subcutaneous Injection) as a single dose
Study NCT04999527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is administered (IV infusion or Subcutaneous Injection) as a single dose
Study NCT05621902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Weekly symptom monitoring
Description: Patients randomized to the intervention arm will be invited to respond to a web-based weekly 11-item signs- and symptoms questionnaire
Study NCT04948736 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined exercise and nutrition intervention
Description: Combined exercise and nutrition intervention for 12 weeks (an introductory phase 3 weeks, an expanded phase 3 weeks, and a maintenance phase 6 weeks).~Exercise intervention (each 60-min session) includes stretching, resistance exercise, and aerobic exercise according to protocol.~Nutritional intervention includes investigating dietary habits and calculate insufficient protein intake using Mini Nutritional Aseessment (MNA) and Korean Protein Assessment Tool (KPAT) to provide customized diet and high protein drink.
Study NCT04948736 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medial care
Description: Conventional medical care service for 12weeks during intervention period. Usual care includes medical check-up and exercise and dietary counseling. They were given a brochure about exercise and protein-rich foods at their first visit.~The control group patients maintain their usual amount of activity and diet during the 6-month evaluation period. usual activity and dietary habits.
Study NCT05607706 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure to maternal odor
Description: Exposure to maternal odor; the shirt worn by the mother is put in the baby's incubator, kangaroo care; mother lays her baby naked between her breasts
Study NCT03879304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multimodal physiotherapy program with RV
Description: Physiotherapy Programm includes: respiratory physiotherapy, stretching, resistance training, aerobic training and adaptation and training with virtual reality glasses and relaxation.
Study NCT03879304 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy program
Description: Multimodal physiotherapy Programm includes: traditional physiotherapy, stretching, massage.
Study NCT06530888 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Process-based Cognitive Behavioral Therapy (PBT)
Description: Intervention planning based on the use of EMA data, feedback of dynamic network analysis and matching of interventions to central nodes of the network.
Study NCT06530888 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine practice (r-PT)
Description: Intervention planning as usual.
Study NCT05320393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PrabotulinumtoxinA-Xvfs
Description: One treatment of 40 units
Study NCT05320393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OnabotulinumtoxinA
Description: One treatment of 20 units
Study NCT05320393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PrabotulinumtoxinA-Xvfs
Description: One treatment of 20 units
Study NCT05066308 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD
Description: Epidiolex, an agent within the anti-epileptic drug class, will be used. Epidiolex, Greenwich Biosciences Inc.'s CBD formulation, is a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring. The drug is formulated from extracts prepared from Cannabis sativa L. plants that have a defined chemical profile and contain consistent levels of CBD as the principal phytocannabinoid. Extracts from these plants are processed to yield pure (>95%) CBD that typically contains less than 0.5% (w/w) THC. Cannabidiol is the active ingredient in Epidiolex; inactive ingredients include dehydrated alcohol, sesame seed oil, strawberry flavor, and sucralose. Of note, CBD has no psychoactive properties.
Study NCT05066308 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo CBD will be identical to the active CBD, a 100 mg/mL purified oral solution, dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring, but with no CBD.
Study NCT05397054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: - Education: Education about risk of high sodium intake, type of sodium, nutrition ingredients
Study NCT05397054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reformulation
Description: - Reformulation: Dietary recommendation in low sodium intake
Study NCT05397054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Environmental change
Description: - Environmental change: Encourage about low sodium intake in community
Study NCT05397054 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Salt meter
Description: - Used salt meter: at least 3 times/wk
Study NCT05397054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: standard treatment
Study NCT05383547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Dexamethasone 10mg+ bortezomib (1.3mg /m2 IV) was administered at D1,D4,D8,D11, one month for 1 cycle, for 2 cycles.
Study NCT05469139 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Portable MRI acquisition
Description: Patients on ECMO will undergo a portable MRI of the brain
Study NCT04397458 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 0.9% saline on each side
Study NCT04397458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 0.25% bupivacaine (50mg) on each side
Study NCT04397458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 3mg preservative-free dexamethasone on each side
Study NCT04878692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Application of Onco-Rash cream
Description: The cream Onco-Rash will be administered topically. The patient will be asked to apply the cream twice a day in the morning and evening for 6 weeks to clean, dry skin on selected target areas of the body, namely: the face, the front of the neck, the front of the chest, the back of the neck and the back of the chest. The product penetrates by gentle massage.